Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July
You may also be interested in...
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.